10x Genomics (NASDAQ:TXG) Issues Quarterly Earnings Results

10x Genomics (NASDAQ:TXG) released its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.19, FiscalAI reports. The business had revenue of $150.84 million for the quarter, compared to analyst estimates of $146.41 million. 10x Genomics had a negative return on equity of 2.89% and a negative net margin of 3.55%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.28) EPS.

Here are the key takeaways from 10x Genomics’ conference call:

• Atera launch is the company’s largest product introduction, enabling spatial whole-transcriptome with single-cell sensitivity at scale and generating “extraordinary” early customer interest and pre-orders ahead of initial H2 2026 shipments.
• Consumables and margins showed strength in Q1 — revenue was $150.8M (up ~9% YoY excluding a one-time settlement), total consumables +13% (spatial consumables +31%), gross margin 70%, and cash balance of $540M (+$113M YoY).
• Instrument revenue declined materially (total instruments -24%, spatial instruments -32%), and management expects a Q2 sequential step-down as some customers delay purchases waiting for Atera; Atera production capacity will be limited in 2026 with roughly ~40 units expected between Q3–Q4.
• Company is positioning for a structural AI and translational tailwind — multiple partnerships and initiatives (e.g., Chan Zuckerberg, Bioptimus) aim to scale biological data generation, expanding the long-term TAM but with uncertain near-term revenue timing.

10x Genomics Stock Performance

10x Genomics stock traded down $0.82 during trading on Friday, reaching $21.60. 4,830,340 shares of the company’s stock were exchanged, compared to its average volume of 2,612,983. The company’s 50-day moving average is $21.53 and its two-hundred day moving average is $18.96. 10x Genomics has a 52-week low of $8.06 and a 52-week high of $26.44. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -127.06 and a beta of 2.05.

Insider Buying and Selling

In related news, CFO Adam Taich sold 8,968 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $166,625.44. Following the completion of the sale, the chief financial officer directly owned 288,417 shares of the company’s stock, valued at approximately $5,358,787.86. This represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 7,826 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $145,407.08. Following the sale, the insider directly owned 424,779 shares of the company’s stock, valued at approximately $7,892,393.82. This trade represents a 1.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 46,426 shares of company stock valued at $902,695. Company insiders own 8.84% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its position in 10x Genomics by 85.9% in the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after buying an additional 1,695 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after buying an additional 5,025 shares during the last quarter. Focus Partners Wealth purchased a new position in 10x Genomics in the 1st quarter valued at about $92,000. CIBC Bancorp USA Inc. purchased a new position in 10x Genomics in the 3rd quarter valued at about $134,000. Finally, EP Wealth Advisors LLC purchased a new position in 10x Genomics in the 4th quarter valued at about $188,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported Q1 revenue of $150.8 million and EPS of -$0.10, both better than Wall Street expectations, with revenue up 9.4% year over year and gross margin improving. Article: 10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
• Positive Sentiment: William Blair reiterated a Buy rating, citing strong Q1 results, an improved growth outlook tied to Atera, and attractive valuation. Article: 10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
• Neutral Sentiment: The company’s earnings call transcript and earnings coverage are drawing attention as investors look for more detail on management’s plans and the sustainability of margin improvement. Article: 10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Despite the beat, 10x Genomics still posted a loss and remains unprofitable, and the company’s FY2026 revenue outlook of $600 million to $625 million is only modestly above consensus. Article: 10x Genomics Reports First Quarter 2026 Financial Results

Analysts Set New Price Targets

Several research firms have recently weighed in on TXG. Barclays lifted their price objective on 10x Genomics from $22.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Leerink Partners reduced their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research note on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a research note on Friday, March 27th. Zacks Research raised 10x Genomics from a “hold” rating to a “strong-buy” rating in a research note on Friday, April 17th. Finally, Bank of America upped their price target on shares of 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average target price of $20.82.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.